APR 15, 2017 07:13 AM PDT
Biomarker Predicts Aggressiveness of a Breast Cancer
WRITTEN BY: Xuan Pham
3 19 631

Though breast cancer is one of the more publicized and well-studied cancer types, treatment for this disease remains imperfect. Many women are overdiagnosed while some don’t receive sufficient treatment to prevent metastasis. But scientists say the guessing game over a breast cancer’s aggressiveness could soon be over. They’ve identified a molecular biomarker that can distinguish between likely non-invasive to likely aggressive breast cancer – critical information that could alter treatment and subsequent outcomes for thousands of women.

The same breast cancer diagnosis does not guarantee the same outcome. In some cases, the breast cancer is so slow-growing that it doesn’t invade and may even be considered benign. By contrast, some breast cancers are so aggressively invasive that doctors have to continually play catch up with the cancer. It’s clear that a cancer as complex as breast cancer can’t have a one-size-fits-all approach. But how can doctors tell from the onset?

By intensely pouring through the expression profiles of about 350 genes associated with breast cancer, researchers from the Whitehead Institute say they’ve found a culprit for cancer aggressiveness. "Early-stage cancers are not all the same. Some are destined to go rogue and should be treated from the outset with this understanding in mind," said Piyush Gupta, the senior study author.

The gene is known as SMARCE1, and is involved in transcriptional activation and repression of other genes. Gupta and colleagues found that SMARCE1 was abundant in early-stage cancers that are more likely to have aggressive outcomes.

"It's clear that SMARCE1 is affecting all of the key players in invasion and metastasis," said Ethan Sokol, the study’s lead author. "It's amazing when you look at the list of the things it's regulating."

"We looked at every step of the metastatic cascade, and the tumor growth at the primary site, as well as the growth at the distant metastases, are not affected by this gene," said Yu-Xiong Feng, the study’s co-author. "Only the invasion is affected by SMARCE1." In other words, SMARCE1 is involved in tumor metastasis.

When SMARCE1 levels were analyzed in tissue samples from hundreds of early stage breast cancer patients, the team found a clear trend: those with higher SMARCE1 expression were more likely to have cancer metastasis. SMARCE1 seemed to be required for breast cancer cells’ escape to secondary sites.

The results provide a clear biomarker for sorting out patients who may require the full arsenal of chemotherapy and radiation, versus those patients in whom careful monitoring may be sufficient. Of course further validation on the SMARCE1 biomarker is needed, but already the study has big implications on how treatment can be personalized to every breast cancer patient’s unique disease.

Additional source: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 08, 2018
Immunology
MAR 08, 2018
How does brain cancer escape the immune system?
One of the most lethal forms of brain cancer owes most of its deadliness to its evasion of the immune system - a nasty trick that prevents T cells and othe
APR 02, 2018
Cancer
APR 02, 2018
Judge Rules that Cancer Warning Labels for Coffee are Needed in California
A deeper look at coffee and acrylamide presence as California law evaluates requirement for placement of cancer causing warning labels on all coffee products and containers.
APR 04, 2018
Cancer
APR 04, 2018
Proposed New Genetic-Clinical Risk Grouping Model for Prostate Cancer
A group of researchers have proposed a new risk grouping model to more accurately/precisely predict the risk of prostate cancer progression though use of gene expression and clinical eval
APR 06, 2018
Cancer
APR 06, 2018
PanCancer Atlas of 33 Cancer Types for Genomic Profile Index Completed by NIH TCGA
The Cancer Genome Atlas project used genomic profiles and bioinformatics to catalogue 33 prevalent types of cancer and is available to the public after 10+ years of analysis.
MAY 21, 2018
Cancer
MAY 21, 2018
Epigenetics & Cancer: DNA Modification Impacts
Epigenetics is defined and outlined as important in gene expression and a possible cause for cancer development & as a target for cancer detection. Researchers are looking at new approaches.
JUN 05, 2018
Cancer
JUN 05, 2018
Precision vs. Personalized Medicine Part I: Precision Approach
So often the phrases "Precision Medicine" and "Personalized Medicine" are used interchangeably. Are they really synonyms? Part I looks at Precision Medicine
Loading Comments...